Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pfizer To Buy King Pharma For $3.6 Billion To Boost Pain Franchise

Executive Summary

Pfizer's acquisition of King Pharmaceuticals will be the Big Pharma's first "bolt-on" purchase since its mega acquisition of Wyeth in 2009 and fits neatly into a strategy it articulated to a jittery Wall Street for months ("Pfizer & Wyeth: Is Mega Merger A Strategic Move Or Desperate Play?" "The Pink Sheet," Jan. 26, 2009.

You may also be interested in...



Opioid Market Snapshot: No Pain, No Gain For Abuse-Deterrence Claims

Abuse-deterrent opioids address a serious unmet need and help differentiate brands from the field of generics, but so far Purdue’s OxyContin remains the only opioid on the market with abuse-deterrent claims, even though FDA recently approved two new opioid analgesics.

Sandoz Pushes Further Into High-Barrier Generics With $1.5B Acquisition of Fougera

Sandoz is acquiring the U.S. generics dermatology business Fougera, which formerly belonged to Nycomed, for $1.5 billion in cash, giving it entry into a highly profitable niche market.

Nycomed US Crowns New Management; Plans New Direction

Now that Japan's Takeda Pharmaceuticals Co. Ltd. is just months away from closing on its €9.6 billion ($13.7 billion) purchase of privately-held Nycomed AS, the Swiss company's investors are planning plenty of changes for the U.S. dermatology business that wasn’t included in the large acquisition.

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS052732

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel